City Therapeutics has inked a new deal with Bausch + Lomb for a gene silencing approach to the eye disorder geographic ...

In contrast, Alnylam is one biotech company which is tipped to deliver on huge expectations, thanks to a rigorous approach to validating its science – RNA interference (RNAi) - a technology ...

The biology of RNA interference has greatly facilitated analysis of loss-of-function phenotypes, but correlating these phenotypes with small-molecule inhibition profiles is not always straightforward.

With its new CEO installed this week, City Therapeutics is aiming to capitalize on the momentum in signing a new deal. The ...

City Therapeutics and Bausch + Lomb have entered into a strategic collaboration focused on the development of an RNA ...

Alnylam Pharmaceuticals CEO Yvonne Greenstreet discusses why RNAI can be used to treat an array of diseases, the company's medicines using this technology, and more. Underwater Volcano Off Coast ...

City Therapeutics partners with Bausch + Lomb to develop an RNAi-based therapy for geographic atrophy, leveraging City’s RNAi ...

Scientists discovered stable RNA on plant leaves that can regulate microbes, revealing a new layer of plant-environment ...

Stifel的认可来自于Alnylam Pharmaceuticals在其领域持续取得的进展。RNAi疗法代表了基因沉默和调控的新方法，允许在基因层面对各种疾病进行靶向治疗。Alnylam一直处于这项技术的前沿，开发了一系列可能解决传统方法难以治疗的疾病的药物。

Vietnam RNAi Therapeutics Market Key Takeaways: The Vietnam RNAi Therapeutics market is undergoing robust growth, fueled by factors such as advancements in RNA interference (RNAi) technology, a ...